As of 29 April 2016, the total number of shares and voting rights in Oasmia Pharmaceutical AB (publ) (”Oasmia”) is 107,209,310.

Oasmia has, in accordance with previously disclosed information, completed a directed issue of 1,666,666 shares, thereby increasing the total number of shares and voting rights by 1,666,666 shares and voting rights. Through the directed issue of shares, the share capital in Oasmia has increased by SEK 166,666.60 from SEK 10,554,264.40 to SEK 10,720,931.

According to the previously disclosed information, in conjunction with the directed issue of shares Oasmia also completed a directed issue of a convertible loan in the amount of SEK 28,000,000. The convertible loan will, if fully converted into shares, result in an increase of the number of shares and voting rights in Oasmia by another 2,393,162 from 107,209,310 (considering the above mentioned issue of shares) to 109,602,472.

The information has been made public in accordance with the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was published on April 29, 2016 at 08.30 CET.

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).